Did doctors get the memo? study checks depakine safety alerts in saudi arabia
NCT ID NCT06714448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at whether healthcare professionals in Saudi Arabia received and understood safety materials about the epilepsy drug Depakine (sodium valproate). Researchers surveyed 455 doctors, pharmacists, and gynecologists to measure their knowledge and behavior. No treatment was given—this was purely a check on how well risk warnings are reaching prescribers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
455 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
In this survey-based study, the data will be collected from each healthcare professional participant in Saudi Arabia once at a certain time. However, the study will take 7 months, from 30 November 2024 to 30 May 2025, to collect the required number of responses.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthcare professionals working only in Saudi Arabia AND * Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR * Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR * Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion Exclusion Criteria: * Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies) * Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome * Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\]) * Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epilepsy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lavender and lullabies help kids with epilepsy sleep better?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a Comfort-Focused education program improve life with epilepsy?
- Can video games rewire young brains after injury?
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy drug candidate put to the test in healthy volunteers